About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker QGEN · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Sep 24, 2026QIAstat-Dx BCID GN Plus AMR PanelQGEN
Qiagen GmbH
Device clearance (510(k))
Traditional
K262168 ↗
Aug 6, 2026QIAstat-Dx BCID GPF Plus AMR PanelQGEN
Qiagen GmbH
Device clearance (510(k))
Traditional
K254194 ↗
May 6, 2026QIAGEN therascreen® FGFR RGQ RT-PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Real-Time Process
P180043 ↗
Mar 9, 2026QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2…QGEN
Qiagen GmbH
Device clearance (510(k))
Traditional
K254032 ↗
Nov 21, 2025QuantiFERON-TB Gold Plus Test
TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS
QGEN
Qiagen
Device approval (PMA), supplement
Real-Time Process
P010033 ↗
Oct 22, 2025therascreen® PIK3CA RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track
P190001 ↗
Oct 22, 2025QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2…QGEN
Qiagen GmbH
Device clearance (510(k))
Traditional
K252329 ↗
Oct 3, 2025QIAGEN therascreen® FGFR RGQ RT-PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track
P180043 ↗
Aug 27, 2025QIAstat-Dx Respiratory Panel Plus; QIAstat-Dx Respiratory P…QGEN
Qiagen GmbH
Device clearance (510(k))
Traditional
K250080 ↗
Feb 28, 2025QIAstat-Dx GI Panel 2 Mini BQGEN
Qiagen GmbH
Device clearance (510(k))
Special
K250324 ↗
Jan 16, 2025therascreen® KRAS RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track
P110027 ↗
Jan 8, 2025QIAstat-Dx GI Panel 2 Mini B&VQGEN
Qiagen GmbH
Device clearance (510(k))
Special
K243813 ↗
Dec 6, 2024therascreen FGFR RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track No User Fee
P180043 ↗
Oct 29, 2024QIAstat-Dx Meningitis/Encephalitis (ME) PanelQGEN
Qiagen GmbH
Device clearance (510(k))
Traditional
K242256 ↗
Oct 25, 2024QIAstat-Dx Respiratory Panel MiniQGEN
Qiagen GmbH
Device clearance (510(k))
Special
K242353 ↗
Jun 21, 2024therascreen® KRAS RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track
P110027 ↗
May 31, 2024QIAstat-Dx Gastrointestinal Panel 2QGEN
Qiagen GmbH
Device clearance (510(k))
Traditional
K220062 ↗
May 10, 2024QIAstat-Dx® Respiratory Panel PlusQGEN
Qiagen GmbH
Device clearance (510(k))
Traditional
K233100 ↗
Oct 6, 2023QIAGEN therascreen® KRAS RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Special (Immediate Track)
P110027 ↗
Jun 29, 2023therascreen PDGFRA RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA)P210002 ↗
Jan 24, 2023QUANTIFERON®-TB Gold Plus Test
TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS
QGEN
Qiagen
Device approval (PMA), supplement
Real-Time Process
P010033 ↗
Dec 12, 2022therascreen KRAS RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track
P110027 ↗
Jun 17, 2022therascreen KRAS RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Special (Immediate Track)
P110027 ↗
Dec 13, 2021QuantiFERON®-TB Gold, QuantiFERON®-TB Gold Plus
TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS
QGEN
Qiagen
Device approval (PMA), supplement
Normal 180 Day Track
P010033 ↗
Nov 16, 2021therascreen FGFR RGQ RT-PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Real-Time Process
P180043 ↗
Jul 7, 2021therascreen EGFR RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Real-Time Process
P120022 ↗
May 28, 2021therascreen KRAS RGQ PCR KIT
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Panel Track
P110027 ↗
Aug 18, 2020therascreen FGFR RGQ RT-PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track
P180043 ↗
Apr 15, 2020therascreen BRAF V600E RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA)P190026 ↗
Oct 11, 2019PartoSure Test
Placental alpha microglobulin-1 immunoassay
QGEN
Qiagen, Inc.
Device approval (PMA), supplement
Normal 180 Day Track No User Fee
P160052 ↗
Sep 26, 2019therascreen EGFR RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Special (Immediate Track)
P120022 ↗
May 24, 2019therascreen PIK3CA RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA)P190004 ↗
May 24, 2019therascreen PIK3CA RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA)P190001 ↗
May 18, 2019QIAstat-Dx Respiratory PanelQGEN
Qiagen GmbH
Device clearance (510(k))
Traditional
K183597 ↗
Apr 29, 2019Quantiferon - TB Gold Plus Test
TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS
QGEN
Qiagen
Device approval (PMA), supplement
Real-Time Process
P010033 ↗
Apr 12, 2019therascreen FGFR RGQ RT-PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA)P180043 ↗
Oct 30, 2018QuantiFERON-TB Gold Test / QuantiFERON TB Gold Plus Test
TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS
QGEN
Qiagen
Device approval (PMA), supplement
Real-Time Process
P010033 ↗
Sep 27, 2018therascreen EGFR RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track
P120022 ↗
Aug 24, 2018QuantiFeron TB Gold and QuantiFeron TB Gold Plus
TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS
QGEN
Qiagen
Device approval (PMA), supplement
135 Review Track For 30-Day Notice
P010033 ↗
Apr 11, 2018PartoSure test
Placental alpha microglobulin-1 immunoassay
QGEN
Qiagen, Inc.
Device approval (PMA)P160052 ↗
Mar 13, 2018artus CMV RGQ MDx Kit and artus CMV QS-RGQ MDx Kit
Cytomegalovirus (cmv) dna quantitative assay
QGEN
Qiagen, Inc.
Device approval (PMA), supplement
135 Review Track For 30-Day Notice
P130027 ↗
Jan 12, 2018Therascreen EGFR RGQ PCR Kit
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track
P120022 ↗
Jan 12, 2018ipsogen JAK2 RGQ PCR KitQGEN
Qiagen, Inc.
Device clearance (510(k))
Traditional
K172287 ↗
Nov 15, 2017Artus CMV RGQ and QS-RGQ MDx Kit
Cytomegalovirus (cmv) dna quantitative assay
QGEN
Qiagen, Inc.
Device approval (PMA), supplement
Normal 180 Day Track
P130027 ↗
Jun 7, 2017QUANTTFERON-TB GOLD Plus
TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS
QGEN
Qiagen
Device approval (PMA), supplement
Normal 180 Day Track
P010033 ↗
Jun 2, 2017ARTUS CMV RGQ MDX KIT
Cytomegalovirus (cmv) dna quantitative assay
QGEN
Qiagen, Inc.
Device approval (PMA), supplement
Normal 180 Day Track
P130027 ↗
May 19, 2017THERASCREEN EGFR RGQ PCR KIT
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track
P120022 ↗
Mar 27, 2017ipsogen JAK2 RGQ PCR KitQGEN
Qiagen, Inc.
Device clearance (510(k))
De Novo
DEN160028 ↗
Nov 9, 2015THERASCREEN EGFR RGQ PCR KIT
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track No User Fee
P120022 ↗
Nov 9, 2015THERASCREEN KRAS RGQ PCR KIT
Somatic gene mutation detection system
QGEN
Qiagen GmbH
Device approval (PMA), supplement
Normal 180 Day Track No User Fee
P110027 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:36 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates